Life sciences firms may never produce products, so valuation is prospective rather than embodied
Evidence
When it comes to the bio-economy, then, these valuation practices problematize inherent or embodied notions of value, especially through their focus on an organizational entity (i.e., firm) rather than commodity production. This is because a life sciences firm likely produces no products for sale and its likelihood of doing so in the future is highly uncertain, if not highly unlikely. — Kean Birch, Rethinking Value in the Bio-economy, 38
Categorization
- XREF: Contrasts with commodity-production frameworks of classical political economy that anchor value in embodied labor. — connects to: Biotech firms can be valued as strategic acquisitions, not for their revenue — Kean Birch, Rethinking Value in the Bio-economy:…, 76; In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. — Kean Birch, Rethinking Value in the Bio-economy:…, 106; Analyzing bio-economy value requires focusing on assets rather than commodities — Kean Birch, Rethinking Value in the Bio-economy:…, 68 (+2 more)
Related
- Understanding value requires studying the assets underpinning firm valuation, not commodity production. (similarity 0.88)
- Value in the bio-economy is managed through asset governance, not product sales. (similarity 0.87)
- In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. (similarity 0.86)
- Analyzing bio-economy value requires focusing on assets rather than commodities (similarity 0.85)
- Biotech firms can be valued as strategic acquisitions, not for their revenue (similarity 0.84)
- Value in the bio-economy is better theorized through assetization than commodification. (similarity 0.81)
- Value is constituted by knowledge and practice, not merely hype. (similarity 0.81)
- Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. (similarity 0.81)
- Bio-economy valuation practices are not peculiar to that sector. (similarity 0.81)
- Asset value derives from future earnings rather than intrinsic commodity value (similarity 0.81)
- Accounting for biological assets reflects chosen methods, not intrinsic biological qualities (similarity 0.79)
- Value is not inherent in things but achieved through capitalization practices. (similarity 0.79)
Broader Connections
- Biotech firms can be valued as strategic acquisitions, not for their revenue
#corroborates(0.85) — Kean Birch, Rethinking Value in the Bio-economy, 76 - In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value.
#expands(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 106 - Analyzing bio-economy value requires focusing on assets rather than commodities
#corroborates(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 68 - Understanding value requires studying the assets underpinning firm valuation, not commodity production.
#corroborates(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 39 - Speculation prices assets by imagined future appeal to others, not actual value.
#corroborates(0.75) — Aris Komporozos-Athanasiou, Speculative Communities, 138